Radiprodil, a selective GluN2B negative allosteric modulator, rescues audiogenic seizures in mice carrying the GluN2A(N615S) mutation
Authors:
Open Access
- 26 March 2024
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 181 (12) , 1886-1894
Abstract
Background and Purpose: GRIN‐related disorders are neurodevelopmental disorders caused by mutations in N‐methyl‐D‐aspartate receptor (NMDAR) subunit genes. A large fraction of these mutations lead to a ‘gain of function’ (GoF) of the NMDAR. Patients present with a range of symptoms including epilepsy, intellectual disability, behavioural and motor. Controlling seizures is a significant unmet medical need in most patients with GRIN‐related disorders. Although several hundred GRIN mutations have been identified in humans, until recently none of the mouse models carrying Grin mutations/deletions showed an epileptic phenotype. The two recent exceptions both carry mutations of GluN2A. The aim of this study was to assess the efficacy of radiprodil, a selective negative allosteric modulator of GluN2B‐containing NMDARs, in counteracting audiogenic seizures (AGS) in a murine model carrying the GluN2A(N615S) homozygous mutation (Grin2aS/S mice).Experimental Approach: Grin2aS/S mice were acutely treated with radiprodil at different doses before the presentation of a high‐frequency acoustic stimulus commonly used for AGS induction.Key Results: Radiprodil significantly and dose‐dependently reduced the onset and severity of AGS in Grin2aS/S mice. Surprisingly, the results revealed a sex‐dependent difference in AGS susceptibility and in the dose‐dependent protection of radiprodil in the two genders. Specifically, radiprodil was more effective in female versus male mice.Conclusion and Implications: Overall, our data clearly show that radiprodil, a GluN2B selective negative allosteric modulator, may have the potential to control seizures in patients with GRIN2A GoF mutations. Further studies are warranted to better understand the sex‐dependent effects observed in this study.Keywords
All Related Versions
This publication has 31 references indexed in Scilit:
- Functional effects of disease-associated variants reveal that the S1–M1 linker of the NMDA receptor critically controls channel openingCellular and Molecular Life Sciences, 2023
- Clinical and therapeutic significance of genetic variation in the GRIN gene family encoding NMDARsNeuropharmacology, 2021
- Radiprodil, a NR2B negative allosteric modulator, from bench to bedside in infantile spasm syndromeAnnals of Clinical and Translational Neurology, 2020
- De novo mutations and rare variants occurring in NMDA receptorsCurrent Opinion in Physiology, 2017
- GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B-containing NMDA receptorsNeuropharmacology, 2017
- The NMDA receptor complex as a therapeutic target in epilepsy: a reviewEpilepsy & Behavior, 2011
- Rapid Bidirectional Switching of Synaptic NMDA ReceptorsNeuron, 2007
- Glutamate receptor channel signaturesTrends in Pharmacological Sciences, 2001
- Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal deathNeuron, 1994
- Developmental and regional expression in the rat brain and functional properties of four NMDA receptorsNeuron, 1994